Spanish registry for adverse events of biological therapy in rheumatic diseases (BIOBADASER): State report, January 26th, 2006;Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de la situación, 26 de enero de 2006

Reumatologia Clinica

Volumn 3, Issue 1, 2007, Pages 4-20

  Descalzo, Miguel Ángel ^a   Montero, Dolores ^b   Erra, Alba ^c   Marsal, Sara ^c   Fernández Castro, Mónica ^d   Mulero, Juan ^d   Luis Andréu, José ^d   Rodríguez Gómez, Manuel ^e   Larrosa Pardo, Marta ^f   Casado, Enrique ^f   Sirvent, Elena Leonor ^g   Reina, Delia ^g   García Gómez, Carmen ^g   Joven, Beatriz ^h   Carreira, Patricia ^h   Hernández, M Victoria ⁱ   Loza, Estibaliz ^j   Alonso, Alberto ^k   Uriarte, Esther ^k   Pantoja, Lucía ^l   Valvanera Pinillos, M ^l   Mariné, Teresa ^m   García de Vicuña, Rosario ⁿ   Ortiz, Ana M ⁿ   González Álvaro, Isidoro ⁿ   Laffón, Armando ⁿ   Álvaro Gracia, José M ⁿ   Díaz López, César ^o   Rodríguez de La Serna, Arturo ^o   Loza, Eduardo ^p   Irigoyen, M Victoria ^q   Ureña, Inmaculada ^q   Coret, Virginia ^q   Vela, Paloma ^r   Pascual Gómez, Eliseo ^r   Belmonte, Miguel Ángel ^s   Beltrán, Juan ^s   Lerma, Juan José ^s   Liz, Myriam ^t   Gelman, Saul Mario ^u   Ciruelo, Elena ^v   Tomero, Eva ^v   Amengual, Olga ^v   Cobeta, Juan Carlos ^w   Saiz, Encarnación ^x   Gálvez, José ^x   Iglesias de La Torre, Gerardo ^y   Roselló, Rosa ^z   Vźquez, Carlos ^z   Valdazo, Juan Pablo ^aa   Tena, Xavier ^ab   Ortiz, Vera ^ab   Fernández Prada, Manuel ^ac   Piqueras, José Antonio ^ac   Tornero Molina, Jesús ^ac   Cebrián, Laura ^ad   Carreño, Luis ^ad   García Borras, Juan José ^ae   Javier Manero, Francisco ^af   Pujol, Manel ^ag   Granados, Josep ^ag   Cuadra, José Luis ^ah   Javier Paulino, F ^ah   Paulino, Marcos ^ah   Maiz, Olga ^ai   Barastay, Estibaliz ^ai   Figueroa, Manuel ^ai   Torres, Carmen ^aj   Corteguera, Montserrat ^aj   Rodríguez Lozano, Carlos ^ak   Francisco Hernńadez, Félix ^ak   Rua Figueroa, Iñigo ^ak   Illera, Oscar ^al   Zea, Antonio C ^al   García de La Peña, Paloma ^al   Valero, Marta ^al   Aznar, Emilia ^am   Gutiérrez, Ricardo ^am   Cruz Valenciano, Ana ^an   Crespo, Manuel ^an   Cabero, Félix ^an   Ruiz Jimeno, M Teresa ^ao   Fiter, Jordi ^ap   Espadaler, Luis ^ap   Vesga, Juan Carlos ^aq   Cuende, Eduardo ^aq   Sánchez Andrada, Sagrario ^ar   Rodríguez Valverde, Vicente ^ar   Ferraz, Iván ^as   González, Tomas ^as   Marenco, José Luis ^at   Rejón, Eduardo ^at   Collantes, Eduardo ^am   Castro, M Carmen ^am   Montes de Oca, José V ^au   Navarro, Federico ^au   Javier Toyos, Francisco ^au   Marras, Carlos ^av   Linares, Luis Francisco ^av   more..

^a UNIDAD DE INVESTIGACIÓN   (Spain)

^b Division de Farmacoepidemiologia y Farmacovigilancia   (Spain)

^c Centre Sanitari Vall d'Hebron   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e Servicio Gallego de Salud   (Spain)

^f Centro Hospitalario del Parc Taulí   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ Hospital Clínic i Provincial   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL DE CRUCES   (Spain)

^l HOSPITAL EL BIERZO   (Spain)

^m HOSPITAL DE L ESPERIT SANT   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^o HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^p Instituto de Investigación Sanitaria de Navarra   (Spain)

^q Hospital General Carlos Haya   (Spain)

^r HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^s HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^t University Hospital of Santiago de Compostela   (Spain)

^u Hospital General de Manresa   (Spain)

^v HOSPITAL GENERAL DE SEGOVIA   (Spain)

^w Hospital General de Teruel Obispo Polanco   (Spain)

^x Hospital General Morales Meseguer   (Spain)

^y HOSPITAL RÍO CARRIÓN   (Spain)

^z Hospital General San Jorge   (Spain)

^aa HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^ab HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^ac HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^ad HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^ae HOSPITAL UNIVERSITARIO LA FE   (Spain)

^af HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^ag HOSPITAL MÚTUA DE TERRASSA   (Spain)

^ah Hospital Nuestra Señora del Carmen   (Spain)

^ai Hospital de Donosti   (Spain)

^aj HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^ak HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^al HOSPITAL RAMÓN Y CAJAL   (Spain)

^am HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^an HOSPITAL SEVERO OCHOA   (Spain)

^ao Hospital Comarcal Sierrallana   (Spain)

^ap HOSPITAL SON DURETA   (Spain)

^aq HOSPITAL TXAGORRITXU   (Spain)

^ar HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^as HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^at HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^au HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^av HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

more..

Author keywords

Adverse events; Biological therapies; Follow up; Registry

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ABDOMINAL PAIN; ACCIDENT; ACNE; ADENOCARCINOMA; AGORAPHOBIA; ALOPECIA; AMNESIA; AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; ANAPHYLACTIC SHOCK; ANEMIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ANUS FISTULA; AORTA ANEURYSM; AORTA ARCH SYNDROME; AORTA RUPTURE; APPENDICITIS; ARTHROPATHY; ARTICLE; ASTHENIA; ATLANTOAXIAL DISLOCATION; AVASCULAR NECROSIS; BACTERIAL ENDOCARDITIS; BASAL CELL CARCINOMA; BEHCET DISEASE; BILIARY COLIC; BLOOD DISEASE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INFECTION; BREAST CARCINOMA; BRONCHIOLITIS OBLITERANS; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CERVICOBRACHIAL NEURALGIA; COLON CARCINOMA; COLON POLYP; COMBINATION CHEMOTHERAPY; CONFUSION; CONVULSION; COR PULMONALE; CORNEA ULCER; CROHN DISEASE; DEMENTIA; DEPRESSION; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DIGESTIVE SYSTEM HEMORRHAGE; DIPLOPIA; DISEASE REGISTRY; DISKITIS; DIVERTICULITIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INFUSION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DUODENITIS; DUPUYTREN CONTRACTURE; DYSPEPSIA; DYSPNEA; DYSURIA; ENDOCRINE DISEASE; ENDOMETRIOSIS; EOSINOPHILIA; EPISTAXIS; ERYTHEMA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; ESOPHAGITIS; ESSENTIAL TREMOR; EYE DISEASE; EYE PAIN; FELTY SYNDROME; GASTRITIS; GINGIVA BLEEDING; GINGIVA TUMOR; GLAUCOMA; GLIOBLASTOMA; GRANULOMA ANNULARE; GYNECOLOGIC DISEASE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEMATOMA; HEMATURIA; HEMOPTYSIS; HEMORRHAGIC CYSTITIS; HERNIA; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPERTHYROIDISM; HYPERTRICHOSIS; HYPOCALCEMIA; HYPOTHYROIDISM; HYSTERIA; IMPOTENCE; INFECTION; INFECTION RATE; INJECTION SITE INFLAMMATION; INSOMNIA; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; INTRAOCULAR HEMORRHAGE; IRITIS; ISCHIALGIA; JUVENILE RHEUMATOID ARTHRITIS; KERATOACANTHOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PAIN; LARYNX TUMOR; LEUKOPENIA; LIBIDO DISORDER; LICHEN PLANUS; LICHEN STRIATUS; LIPOMA; LIVER DYSFUNCTION; LONG TERM CARE; LUNG CARCINOMA; LUNG DISEASE; LUNG EMBOLISM; LUNG FIBROSIS; LUNG TUBERCULOSIS; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOMA; MELANOMA; MENINGIOMA; MENSTRUATION DISORDER; MENTAL DISEASE; MILIARY TUBERCULOSIS; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MOUTH ULCER; MUCKLE WELLS SYNDROME; MYASTHENIA GRAVIS; NEPHROLITHIASIS; NEURITIS; NEUROLOGIC DISEASE; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; ODYNOPHAGIA; OVARY CARCINOMA; PAIN; PANCREAS CARCINOMA; PANCREATITIS; PANCYTOPENIA; PATHOLOGIC FRACTURE; PEPTIC ULCER; PERICARDITIS; PERIPHERAL EDEMA; PERIPHERAL ISCHEMIA; PERITONEUM CANCER; PHLEBITIS; PLEURA DISEASE; PNEUMONIA; PNEUMOTHORAX; POLYARTERITIS NODOSA; POLYARTHRITIS; POLYCHONDRITIS; POLYMYOSITIS; POLYNEUROPATHY; POSTTRAUMATIC ARTHROPATHY; PREVENTIVE MEDICINE; PROSTATE CARCINOMA; PROSTATISM; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PSYCHOSIS; PTOSIS; PYODERMA GANGRENOSUM; RECTUM HEMORRHAGE; REITER SYNDROME; RESPIRATORY FAILURE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHINITIS; SAPHO SYNDROME; SARCOIDOSIS; SCLERITIS; SCLERODERMA; SEBORRHEA; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SJOEGREN SYNDROME; SKIN DEFECT; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN ULCER; SPAIN; SQUAMOUS CELL CARCINOMA; STOMACH PERFORATION; SURVIVAL; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; TENDON RUPTURE; THORAX PAIN; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT DURATION; TRIGEMINUS NEURALGIA; TUBERCULOSIS; ULCERATIVE COLITIS; URINARY TRACT DISEASE; URTICARIA; UVEITIS; VALVULAR HEART DISEASE; VASCULITIS; VEIN THROMBOSIS; VERTIGO; VISUAL DISORDER; VITILIGO; VITREOUS DISEASE; WEGENER GRANULOMATOSIS; XANTHOMA;

EID: 34047265463     PISSN: 1699258X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1699-258X(07)73593-3     Document Type: Article

References (11)

1. Lipani JA, Strand V, Johnson K, Woodworth T, Furst D, Singh G, et al. A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid artritis. J Rheumatol. 2001;28:1170-3.
2. Carmona L, González I, Balsa A, Angel Belmonte M, Tena X, Sanmartí R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis. 2003;62:897-900.
3. Comité Científico de BIOBADASER. BIOBADASER: registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas. Rev Esp Reumatol. 2002;29:292-9.
4. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Comité Científico de BIOBADASER. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-7.
5. Caminero JA, Cayla JA, Lara N, Working Group on the Current Status of Tuberculosis in Spain. Evaluation of tuberculosis trends in Spain, 1991-1999. Int J Tuberc Lung Dis. 2003;7:236-42.
6. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003;29:185-202.
7. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology. 2003;42:617-21.
8. Ellerin T, Rubin R, Weinblatt M. Infections and anti-tumor necrosis factor therapy. Arthritis Rheum. 2003;48:3013-22.
9. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol. 2002; Suppl 65:33-8.
10. Agencia del Medicamento y Productos Sanitarios. Nota informativa de la Agencia Española del Medicamento sobre riesgo de medicamentos. Ref: 2002/01. February 2002 [citado 13 Feb 2005]. Disponible en: www.age-med.es/documentos/notasPrensa/csmh/2002/ cont_Infliximab_feb02∏.htm
11. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-72.